BRD4 and congenital heart disease: Furthermore, given the central role of BRD4 in the control of fibrosis across organ systems, BET inhibition is ideally suited to treat concomitant multi-organ fibrosis, such as occurs in cardiorenal syndrome, cardiopulmonary disease, and liver fibrosis resulting from the Fontan operation for single-ventricle congenital heart disease.